Biotest is one of the manufacturers with a relatively complete variety of POCT diagnostic reagents in the world. Relying on strong independent innovation and management capabilities, Biotest has established a rapid immunodiagnosis platform, a POCT application technology platform, a biological core raw material technology platform, an automated production technology platform and other industrial technology platforms. On this basis, it has independently researched and developed a technology platform that includes reproduction Hundreds of products in five major product series, including health testing, drug abuse (drug) testing, infectious disease testing, tumor marker testing, and myocardial marker testing, are widely used in domestic and foreign medical institutions, judicial testing systems, and third parties. Testing institutions, disease prevention and control centers, blood collection stations, private clinics, etc.
Our Products
The company's main products are developed based on the preparation and labeling technology of colloidal gold/latex/fluorescent particles, immunochromatography technology, monoclonal antibody technology, etc. Compared with traditional diagnostic methods, they have strong specificity, high sensitivity, it is simple, fast, and cost-effective. Generally does not require special equipment, and suitable for large-scale screening. At the same time, Biotest continues to invest in molecular diagnostic technology platform and animal disease detection service platform related technology reserves, as a strategic technology platform, laying the foundation for continuous business technology innovation in the future.
Our Patents
Since its establishment, the company has focused on research in the field of biotechnology and R&D of bio-high-tech products. As of December 2023, the company has 230 patented technologies, including 171 domestic patents (9 invention patents) and 59 overseas patents (7 Invention patents).
Obtained 45 NMPA certificates, EU CE certificates covering 603 products, and 3 US FDA 510(k) certificates covering 21 test products. Products are sold to more than 100 countries and regions around the world.
Why choose Biotest
Here Are two Reasons Why You Choose Us
To provide you with satisfactory service
In 2015, Hangzhou Biotest Biotech Co., Ltd completed the acquisition of Advin Biotechnology Co., Ltd. of the United States. With the technology and talent advantages of the Silicon Valley of the United States, and adhering to the strategy of global research and development, Biotest not only established to provide innovative, timely, high-quality products for the global market, but also offering solution program and development center.